Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06446570
Status:
COMPLETED
Last Update Posted:
2024-06-06
First Post:
2024-05-31
Brief Title:
Phase II Study of DurvalumabMEDI4736 Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Sponsor:
Seoul National University Hospital
Organization:
Seoul National University Hospital
Study Overview
Official Title:
Phase II Study of Durvalumab - Tremelimumab in Patients With Recurrent andor Metastatic Head and Neck Squamous Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II study of Durvalumab- Tremelimumab in patients with recurred metastatic head and neck squamous cell carcinoma
Detailed Description:
Open multicenter single arm phase II biomarker driven umbrella trial for head and neck squamous cell carcinoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None